| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S11899-007-0017-Z |
| P8608 | Fatcat ID | release_i7dkiy5qfrgy5ifig3ex63naxq |
| P698 | PubMed publication ID | 20425360 |
| P2093 | author name string | Shaji Kumar | |
| P2860 | cites work | Reduced bone marrow stem cell pool and progenitor mobilisation in multiple myeloma after melphalan treatment | Q28378324 |
| Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergrou | Q33340726 | ||
| High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma | Q34195428 | ||
| The role of stem cell transplantation in multiple myeloma | Q34914232 | ||
| Comparison of autologous bone marrow transplantation and peripheral blood stem cell transplantation after first remission induction treatment in multiple myeloma. | Q40426422 | ||
| A combination of dexamethasone, cyclophosphamide, etoposide, and cisplatin is less toxic and more effective than high-dose cyclophosphamide for peripheral stem cell mobilization in multiple myeloma. | Q40573378 | ||
| Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high-dose cyclophosphamide plus GM-CSF vs G-CSF alone. | Q40647771 | ||
| Differential mobilization of myeloma cells and normal hematopoietic stem cells in multiple myeloma after treatment with cyclophosphamide and granulocyte-macrophage colony-stimulating factor. | Q42557617 | ||
| High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. | Q43573096 | ||
| The role of second autografts in the management of myeloma at first relapse. | Q44204181 | ||
| Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma | Q44208130 | ||
| Single versus double autologous stem-cell transplantation for multiple myeloma. | Q44706045 | ||
| Relapse of multiple myeloma after autologous transplantation: survival after salvage therapy | Q44746488 | ||
| Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant | Q44758863 | ||
| Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma | Q44899834 | ||
| Results of a multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplant | Q45205050 | ||
| Autologous stem cell transplantation in multiple myeloma: outcome in patients with renal failure | Q46536755 | ||
| High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe | Q46795068 | ||
| Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. | Q46907944 | ||
| Maintenance thalidomide following single cycle autologous peripheral blood stem cell transplant in patients with multiple myeloma | Q47599429 | ||
| A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results | Q47720657 | ||
| Faster engraftment but no reduction in infectious complications after peripheral blood stem cell transplantation compared to autologous bone marrow transplantation | Q47722490 | ||
| Successful mobilization of peripheral blood stem cells in heavily pretreated myeloma patients with G-CSF alone | Q47734023 | ||
| High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial | Q57780128 | ||
| Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial | Q59650507 | ||
| The development of high dose melphalan and of autologous bone marrow transplantation in the treatment of multiple myeloma: Royal Marsden and St Bartholomew's Hospital studies | Q68149118 | ||
| High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma | Q68180035 | ||
| A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome | Q71123629 | ||
| Mobilization of peripheral blood progenitor cells with high-dose cyclophosphamide (4 or 7 g/m2) and granulocyte colony-stimulating factor in patients with multiple myeloma | Q71331096 | ||
| Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome | Q71611831 | ||
| High-dose intravenous melphalan for plasma-cell leukaemia and myeloma | Q72562480 | ||
| A comparison of toxicity following two different doses of cyclophosphamide for mobilization of peripheral blood progenitor cells in 116 multiple myeloma patients | Q74286832 | ||
| Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial | Q74453880 | ||
| Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years | Q74502702 | ||
| Leukapheresis products in multiple myeloma: lower tumor load after mobilization with cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) compared with G-CSF alone | Q77206396 | ||
| Age is not a prognostic variable with autotransplants for multiple myeloma | Q77720616 | ||
| Total therapy with tandem transplants for newly diagnosed multiple myeloma | Q77720623 | ||
| Are myeloma patients with renal failure candidates for autologous stem cell transplantation? | Q77838071 | ||
| Benefit and timing of second transplantations in multiple myeloma: clinical findings and methodological limitations in a European Group for Blood and Marrow Transplantation registry study | Q79811602 | ||
| Maintenance therapy with thalidomide improves survival in patients with multiple myeloma | Q80011690 | ||
| A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma | Q82400928 | ||
| Prolonged overall survival with second on-demand autologous transplant in multiple myeloma | Q83300465 | ||
| P433 | issue | 2 | |
| P921 | main subject | stem cell transplantation | Q65592366 |
| P304 | page(s) | 121-127 | |
| P577 | publication date | 2007-05-01 | |
| P1433 | published in | Current hematologic malignancy reports | Q26842233 |
| P1476 | title | Role of autologous stem cell transplantation in multiple myeloma | |
| P478 | volume | 2 |
Search more.